Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

Figure 1 Comparison of glucose changes before and after treatment in two groups of patients. A: The changes of fasting plasma glucose and 2-h postprandial blood glucose before and after treatment in the two groups; B: The changes of glycated hemoglobin before and after treatment in the two groups. ^cP < 0.001. 2hPG: 2-h postprandial blood glucose; FPG: Fasting plasma glucose; HbAlc: Glycated hemoglobin.